Reported Earnings • Jun 27
Full year 2026 earnings released: EPS: JP¥9.95 (vs JP¥32.42 loss in FY 2025) Full year 2026 results: EPS: JP¥9.95 (up from JP¥32.42 loss in FY 2025). Revenue: JP¥69.5b (up 9.5% from FY 2025). Net income: JP¥114.0m (up JP¥481.0m from FY 2025). Profit margin: 0.2% (up from net loss in FY 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Jun 25
Pharmarise Holdings Corporation, Annual General Meeting, Aug 28, 2026 Pharmarise Holdings Corporation, Annual General Meeting, Aug 28, 2026. Buy Or Sell Opportunity • May 28
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 1.2% to JP¥511. The fair value is estimated to be JP¥664, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10.0% over the last 3 years. Meanwhile, the company became loss making. Upcoming Dividend • May 21
Upcoming dividend of JP¥14.00 per share Eligible shareholders must have bought the stock before 28 May 2026. Payment date: 28 August 2026. The company is not currently making a profit but it is cash flow positive. Trailing yield: 2.6%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (2.0%). Announcement • May 13
Pharmarise Holdings Corporation to Report Fiscal Year 2026 Results on Jun 25, 2026 Pharmarise Holdings Corporation announced that they will report fiscal year 2026 results at 9:00 AM, Tokyo Standard Time on Jun 25, 2026 Buy Or Sell Opportunity • Mar 23
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.3% to JP¥506. The fair value is estimated to be JP¥643, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10.0% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Mar 21
Third quarter 2026 earnings released: JP¥10.78 loss per share (vs JP¥14.00 loss in 3Q 2025) Third quarter 2026 results: JP¥10.78 loss per share (improved from JP¥14.00 loss in 3Q 2025). Revenue: JP¥17.0b (up 5.7% from 3Q 2025). Net loss: JP¥124.0m (loss narrowed 22% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Announcement • Jan 31
Pharmarise Holdings Corporation (TSE:2796) agreed to acquire Sankou Medical Co.,Ltd. from Yoichi Sakazume and Kenji Sakazume for ¥1.5 billion. Pharmarise Holdings Corporation (TSE:2796) agreed to acquire Sankou Medical Co.,Ltd. from Yoichi Sakazume and Kenji Sakazume for ¥1.5 billion on January 30, 2026. A cash consideration of ¥1.53 billion will be paid by Pharmarise Holdings Corporation. As part of consideration, ¥1.53 billion is paid towards common equity of Sankou Medical Co.,Ltd. The funds for the share acquisition are planned to be raised through a combination of internal funds and borrowings from financial institutions.
For the period ending March 31, 2025, Sankou Medical Co.,Ltd. reported total revenue of ¥1.38 billion and net income of ¥18 million. As of March 31, 2025, Sankou Medical Co.,Ltd. reported total assets of ¥998 million and total common equity of ¥164 million.
The expected completion of the transaction is February 13, 2026. Declared Dividend • Dec 27
Dividend of JP¥14.00 announced Dividend of JP¥14.00 is the same as last year. Ex-date: 28th May 2026 Payment date: 28th August 2026 Dividend yield will be 2.7%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (28% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. Reported Earnings • Dec 26
Second quarter 2026 earnings released: EPS: JP¥11.26 (vs JP¥1.59 in 2Q 2025) Second quarter 2026 results: EPS: JP¥11.26 (up from JP¥1.59 in 2Q 2025). Revenue: JP¥16.8b (up 10.0% from 2Q 2025). Net income: JP¥129.0m (up JP¥111.0m from 2Q 2025). Profit margin: 0.8% (up from 0.1% in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Announcement • Nov 13
Pharmarise Holdings Corporation to Report Q2, 2026 Results on Dec 25, 2025 Pharmarise Holdings Corporation announced that they will report Q2, 2026 results on Dec 25, 2025 Reported Earnings • Sep 26
First quarter 2026 earnings released: JP¥1.58 loss per share (vs JP¥11.65 loss in 1Q 2025) First quarter 2026 results: JP¥1.58 loss per share (improved from JP¥11.65 loss in 1Q 2025). Revenue: JP¥16.8b (up 10.0% from 1Q 2025). Net loss: JP¥18.0m (loss narrowed 86% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Announcement • Aug 07
Pharmarise Holdings Corporation to Report Q1, 2026 Results on Sep 25, 2025 Pharmarise Holdings Corporation announced that they will report Q1, 2026 results on Sep 25, 2025 Reported Earnings • Jun 27
Full year 2025 earnings released: JP¥32.42 loss per share (vs JP¥33.35 loss in FY 2024) Full year 2025 results: JP¥32.42 loss per share. Revenue: JP¥63.5b (up 17% from FY 2024). Net loss: JP¥367.0m (loss widened 4.6% from FY 2024). Announcement • Jun 26
Pharmarise Holdings Corporation, Annual General Meeting, Aug 27, 2025 Pharmarise Holdings Corporation, Annual General Meeting, Aug 27, 2025. Upcoming Dividend • May 22
Upcoming dividend of JP¥14.00 per share Eligible shareholders must have bought the stock before 29 May 2025. Payment date: 01 September 2025. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 2.9%. Lower than top quartile of Japanese dividend payers (4.0%). Higher than average of industry peers (1.7%). Announcement • May 08
Pharmarise Holdings Corporation to Report Fiscal Year 2025 Results on Jun 25, 2025 Pharmarise Holdings Corporation announced that they will report fiscal year 2025 results on Jun 25, 2025 Reported Earnings • Mar 27
Third quarter 2025 earnings released: JP¥14.00 loss per share (vs JP¥8.36 loss in 3Q 2024) Third quarter 2025 results: JP¥14.00 loss per share (further deteriorated from JP¥8.36 loss in 3Q 2024). Revenue: JP¥16.0b (up 17% from 3Q 2024). Net loss: JP¥159.0m (loss widened 66% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Announcement • Feb 15
Pharmarise Holdings Corporation to Report Q3, 2025 Results on Mar 25, 2025 Pharmarise Holdings Corporation announced that they will report Q3, 2025 results on Mar 25, 2025 Declared Dividend • Dec 27
Dividend of JP¥14.00 announced Shareholders will receive a dividend of JP¥14.00. Ex-date: 29th May 2025 Payment date: 1st September 2025 Dividend yield will be 2.7%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (8% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. Reported Earnings • Dec 26
Second quarter 2025 earnings released: EPS: JP¥1.59 (vs JP¥15.10 in 2Q 2024) Second quarter 2025 results: EPS: JP¥1.59 (down from JP¥15.10 in 2Q 2024). Revenue: JP¥15.3b (up 14% from 2Q 2024). Net income: JP¥18.0m (down 88% from 2Q 2024). Profit margin: 0.1% (down from 1.1% in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Announcement • Oct 31
Pharmarise Holdings Corporation to Report Q2, 2025 Results on Dec 25, 2024 Pharmarise Holdings Corporation announced that they will report Q2, 2025 results on Dec 25, 2024 Reported Earnings • Sep 05
Full year 2024 earnings released: JP¥33.35 loss per share (vs JP¥35.42 profit in FY 2023) Full year 2024 results: JP¥33.35 loss per share (down from JP¥35.42 profit in FY 2023). Revenue: JP¥54.5b (up 4.7% from FY 2023). Net loss: JP¥351.0m (down 205% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Aug 17
Pharmarise Holdings Corporation to Report Q1, 2025 Results on Oct 10, 2024 Pharmarise Holdings Corporation announced that they will report Q1, 2025 results on Oct 10, 2024 Reported Earnings • Jun 30
Full year 2024 earnings released: JP¥33.35 loss per share (vs JP¥35.42 profit in FY 2023) Full year 2024 results: JP¥33.35 loss per share (down from JP¥35.42 profit in FY 2023). Revenue: JP¥54.5b (up 4.7% from FY 2023). Net loss: JP¥351.0m (down 205% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Jun 29
Pharmarise Holdings Corporation, Annual General Meeting, Aug 29, 2024 Pharmarise Holdings Corporation, Annual General Meeting, Aug 29, 2024. Upcoming Dividend • May 23
Upcoming dividend of JP¥20.00 per share Eligible shareholders must have bought the stock before 30 May 2024. Payment date: 02 September 2024. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (1.7%). Announcement • Apr 10
Pharmarise Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024 Pharmarise Holdings Corporation revised consolidated earnings guidance for the fiscal year ending May 31, 2024. For the period, the company expects net sales of JPY 54,086 million, operating profit of JPY 1,056 million and profit attributable to owners of parent of JPY 168 million and earnings per share of JPY 16.01. New Risk • Mar 27
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 68% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (68% net debt to equity). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (JP¥7.21b market cap, or US$47.5m). Reported Earnings • Mar 27
Third quarter 2024 earnings released: JP¥8.36 loss per share (vs JP¥14.43 profit in 3Q 2023) Third quarter 2024 results: JP¥8.36 loss per share (down from JP¥14.43 profit in 3Q 2023). Revenue: JP¥13.7b (up 5.7% from 3Q 2023). Net loss: JP¥96.0m (down 171% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Mar 07
Pharmarise Holdings Corporation to Report Q3, 2024 Results on Mar 25, 2024 Pharmarise Holdings Corporation announced that they will report Q3, 2024 results on Mar 25, 2024 Announcement • Jan 13
Pharmarise Holdings Corporation (TSE:2796) entered into stock transfer agreement to acquire GOOD AID Inc. from Kotoshino Co., Ltd. and Yuta Hattori. Pharmarise Holdings Corporation (TSE:2796) entered into stock transfer agreement to acquire GOOD AID Inc. from Kotoshino Co., Ltd. and Yuta Hattori on January 11, 2024. As part of the transaction, 13,556 shares will be acquired. At time of agreement, Yuta Hattori holds 36.9% stake and Kotoshino holds 36.9%. Kotoshino will purchase remaining shares of GOOD AID by transfer date. For period ended September 2023, GOOD AID reported total assets of ¥1.4 billion, net worth of -¥538 million, sales of ¥3.1 billion, operating income of ¥81 million and net income of ¥72 million. The transaction is expected to complete on January 31, 2024. Announcement • Jan 10
Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024 Pharmarise Holdings Corporation provided consolidated earnings guidance for the fiscal year ending May 31, 2024. For the period, the company expects net sales to be JPY 53,546 million, operating profit to be JPY 1,477 million, profit attributable to owners of parent to be JPY 449 million and earnings per share to be JPY 41.99. Reported Earnings • Dec 26
Second quarter 2024 earnings released: EPS: JP¥15.10 (vs JP¥4.15 loss in 2Q 2023) Second quarter 2024 results: EPS: JP¥15.10 (up from JP¥4.15 loss in 2Q 2023). Revenue: JP¥13.5b (up 4.6% from 2Q 2023). Net income: JP¥150.0m (up JP¥189.0m from 2Q 2023). Profit margin: 1.1% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. New Risk • Dec 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks High level of debt (54% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.7% net profit margin). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥7.45b market cap, or US$52.4m). Announcement • Dec 03
Pharmarise Holdings Corporation to Report Q2, 2024 Results on Dec 25, 2023 Pharmarise Holdings Corporation announced that they will report Q2, 2024 results on Dec 25, 2023 Announcement • Oct 13
Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 Pharmarise Holdings Corporation provided dividend guidance for the fiscal year ending May 31, 2024. For the year, the company expects to pay dividend of JPY 20.00 per share. Announcement • Oct 12
Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending May 31, 2024 Pharmarise Holdings Corporation provided consolidated earnings guidance for the six months and full year of fiscal year ending May 31, 2024. For the six months, the company expects net sales of JPY 26,557 million, operating profit of JPY 833 million, profit attributable to owners of parent of JPY 262 million and earnings per share of JPY 26.92.For the year, the company expects net sales of JPY 53,546 million, operating profit of JPY 1,477 million, profit attributable to owners of parent of JPY 449 million and earnings per share of JPY 46.14. Reported Earnings • Oct 05
First quarter 2024 earnings released: EPS: JP¥13.05 (vs JP¥11.87 in 1Q 2023) First quarter 2024 results: EPS: JP¥13.05 (up from JP¥11.87 in 1Q 2023). Revenue: JP¥13.5b (up 4.7% from 1Q 2023). Net income: JP¥123.0m (up 11% from 1Q 2023). Profit margin: 0.9% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 05
Full year 2023 earnings released: EPS: JP¥35.42 (vs JP¥47.90 in FY 2022) Full year 2023 results: EPS: JP¥35.42 (down from JP¥47.90 in FY 2022). Revenue: JP¥52.0b (flat on FY 2022). Net income: JP¥333.0m (down 26% from FY 2022). Profit margin: 0.6% (down from 0.9% in FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Aug 27
Pharmarise Holdings Corporation to Report Q1, 2024 Results on Oct 11, 2023 Pharmarise Holdings Corporation announced that they will report Q1, 2024 results on Oct 11, 2023 Reported Earnings • Jul 13
Full year 2023 earnings released: EPS: JP¥35.42 (vs JP¥47.90 in FY 2022) Full year 2023 results: EPS: JP¥35.42 (down from JP¥47.90 in FY 2022). Revenue: JP¥52.0b (flat on FY 2022). Net income: JP¥333.0m (down 26% from FY 2022). Profit margin: 0.6% (down from 0.9% in FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • May 27
Pharmarise Holdings Corporation to Report Fiscal Year 2023 Results on Jul 11, 2023 Pharmarise Holdings Corporation announced that they will report fiscal year 2023 results on Jul 11, 2023 Upcoming Dividend • May 23
Upcoming dividend of JP¥14.00 per share at 2.2% yield Eligible shareholders must have bought the stock before 30 May 2023. Payment date: 28 August 2023. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Japanese dividend payers (3.5%). Higher than average of industry peers (1.6%). Reported Earnings • Mar 31
Third quarter 2023 earnings released: EPS: JP¥14.43 (vs JP¥7.70 in 3Q 2022) Third quarter 2023 results: EPS: JP¥14.43 (up from JP¥7.70 in 3Q 2022). Revenue: JP¥13.0b (up 2.4% from 3Q 2022). Net income: JP¥136.0m (up 89% from 3Q 2022). Profit margin: 1.0% (up from 0.6% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 1% per year. Announcement • Feb 15
Pharmarise Holdings Corporation (TSE:2796) entered into basic agreement to acquire Two Dispensing Pharmacies in Mie Prefecture. Pharmarise Holdings Corporation (TSE:2796) entered into basic agreement to acquire Two Dispensing Pharmacies in Mie Prefecture on February 14, 2023. Final agreement is scheduled to occur in Mid April. Reported Earnings • Dec 30
Second quarter 2023 earnings released: JP¥4.15 loss per share (vs JP¥20.05 profit in 2Q 2022) Second quarter 2023 results: JP¥4.15 loss per share (down from JP¥20.05 profit in 2Q 2022). Revenue: JP¥12.9b (flat on 2Q 2022). Net loss: JP¥39.0m (down 121% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Announcement • Nov 27
Pharmarise Holdings Corporation to Report Q2, 2023 Results on Dec 29, 2022 Pharmarise Holdings Corporation announced that they will report Q2, 2023 results on Dec 29, 2022 Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 5 independent directors (7 non-independent directors). Independent External Director Norio Watanabe was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 15
First quarter 2023 earnings released: EPS: JP¥11.87 (vs JP¥6.78 in 1Q 2022) First quarter 2023 results: EPS: JP¥11.87 (up from JP¥6.78 in 1Q 2022). Revenue: JP¥12.9b (down 1.5% from 1Q 2022). Net income: JP¥111.0m (up 76% from 1Q 2022). Profit margin: 0.9% (up from 0.5% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Announcement • Aug 27
Pharmarise Holdings Corporation to Report Q1, 2023 Results on Oct 13, 2022 Pharmarise Holdings Corporation announced that they will report Q1, 2023 results on Oct 13, 2022 Announcement • Jul 13
Pharmarise Holdings Corporation, Annual General Meeting, Aug 25, 2022 Pharmarise Holdings Corporation, Annual General Meeting, Aug 25, 2022. Reported Earnings • Jul 10
Full year 2022 earnings released: EPS: JP¥47.90 (vs JP¥45.78 in FY 2021) Full year 2022 results: EPS: JP¥47.90 (up from JP¥45.78 in FY 2021). Revenue: JP¥51.6b (down 1.4% from FY 2021). Net income: JP¥447.0m (up 4.9% from FY 2021). Profit margin: 0.9% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 24
Pharmarise Holdings Corporation (TSE:2796) agreed to acquire Two Dispensing Pharmacies. Pharmarise Holdings Corporation (TSE:2796) agreed to acquire Two Dispensing Pharmacies on June 22, 2022. Announcement • May 25
Pharmarise Holdings Corporation to Report Fiscal Year 2022 Results on Jul 08, 2022 Pharmarise Holdings Corporation announced that they will report fiscal year 2022 results on Jul 08, 2022 Upcoming Dividend • May 23
Upcoming dividend of JP¥14.00 per share Eligible shareholders must have bought the stock before 30 May 2022. Payment date: 27 August 2022. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (3.7%). In line with average of industry peers (1.8%). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 2 independent directors (10 non-independent directors). Independent External Director Norio Watanabe was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 14
Third quarter 2022 earnings released: EPS: JP¥7.70 (vs JP¥1.40 loss in 3Q 2021) Third quarter 2022 results: EPS: JP¥7.70 (up from JP¥1.40 loss in 3Q 2021). Revenue: JP¥12.7b (flat on 3Q 2021). Net income: JP¥72.0m (up JP¥85.0m from 3Q 2021). Profit margin: 0.6% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Announcement • Apr 07
Pharmarise Holdings Corporation to Report Q3, 2022 Results on Apr 12, 2022 Pharmarise Holdings Corporation announced that they will report Q3, 2022 results on Apr 12, 2022 Reported Earnings • Jan 14
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Second quarter 2022 results: EPS: JP¥20.05 (up from JP¥19.54 in 2Q 2021). Revenue: JP¥12.8b (flat on 2Q 2021). Net income: JP¥187.0m (up 2.7% from 2Q 2021). Profit margin: 1.5% (up from 1.4% in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 15
First quarter 2022 earnings released: EPS JP¥6.78 (vs JP¥5.93 loss in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥13.1b (up 1.4% from 1Q 2021). Net income: JP¥63.0m (up JP¥118.0m from 1Q 2021). Profit margin: 0.5% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 18
Full year 2021 earnings released: EPS JP¥45.78 (vs JP¥61.03 in FY 2020) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: JP¥52.3b (up 2.5% from FY 2020). Net income: JP¥426.0m (down 26% from FY 2020). Profit margin: 0.8% (down from 1.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 22
Upcoming dividend of JP¥14.00 per share Eligible shareholders must have bought the stock before 28 May 2021. Payment date: 27 August 2021. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (3.0%). Higher than average of industry peers (1.5%). Reported Earnings • Apr 17
Third quarter 2021 earnings released: JP¥1.40 loss per share (vs JP¥11.69 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings and control over costs, although revenues were flat. Third quarter 2021 results: Revenue: JP¥12.8b (flat on 3Q 2020). Net loss: JP¥13.0m (down 112% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Mar 03
Pharmarise Holdings Corporation to Report Q3, 2021 Results on Apr 14, 2021 Pharmarise Holdings Corporation announced that they will report Q3, 2021 results on Apr 14, 2021 Reported Earnings • Jan 15
Second quarter 2021 earnings released: EPS JP¥19.54 The company reported a decent second quarter result with improved earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: JP¥12.8b (flat on 2Q 2020). Net income: JP¥182.0m (up 37% from 2Q 2020). Profit margin: 1.4% (up from 1.0% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • Nov 28
Pharmarise Holdings Corporation to Report Q2, 2021 Results on Jan 14, 2021 Pharmarise Holdings Corporation announced that they will report Q2, 2021 results on Jan 14, 2021 Announcement • Aug 31
Pharmarise Holdings Corporation to Report Q1, 2021 Results on Oct 15, 2020 Pharmarise Holdings Corporation announced that they will report Q1, 2021 results on Oct 15, 2020 
